Guardant Health, Inc. - Common Stock (NQ:GH)

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

3 Cash-Burning Stocks with Questionable Fundamentals

October 05, 2026

Performance

52-Week Range 11.0% below 52-week high

170.10

61.0652W Low 191.0552W High

1 Week 11.0% below 1-week high

170.051W Low 191.051W High

Guardant Health, Inc. - Common Stock (GH) traded between $61.06 and $191.05 over the past 52 weeks and last traded at $170.10, 11.0% below its 52-week high. Over the past week it ranged between $170.05 and $191.05.

Past 12 Months

-4.6%

+5.7%

+4.4%

+82.3%

+67.2%

+168.4%

1W -$8.26

1M +$9.12

3M +$7.18

6M +$76.80

YTD +$68.36

1Y +$106.72

GH was +168.4% over the past year, +82.3% over six months, +67.2% year to date, -4.6% in the last week.

12 Months vs Market

+168.4%

DIA

+9.2%

SPY

+15.6%

QQQ

+24.6%

IWM

+12.4%

Over the past 12 months GH returned +168.4% versus DIA (Dow) +9.2%, SPY (S&P 500) +15.6%, QQQ (Nasdaq 100) +24.6% and IWM (Russell 2000) +12.4%.

Volume & Liquidity 0.36× 3-mo avg

Today 731,811 3-mo avg 2.0M

2.1M

1.9M

2.0M

2.4M

YTD

2.2M

2.3M

GH most recently traded 731,811 shares against a 3-month average daily volume of 2.0M.

More News

1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore

September 29, 2026

September 21, 2026

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗

July 30, 2026

Via Chartmill

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

September 15, 2026

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

September 14, 2026

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

September 09, 2026

Business Insider Names Guardant Health One of America's Most Innovative Businesses

September 08, 2026

1 Growth Stock to Add to Your Roster and 2 We Turn Down

September 08, 2026

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

September 04, 2026

Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

September 01, 2026

Why Rule Breakers Buy a Stock That's Already "Won" ↗

August 31, 2026

Via The Motley Fool

Guardant Health to Appeal Federal District Court Judgment

August 24, 2026

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗

August 14, 2026

Via MarketBeat

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗

August 12, 2026

Via The Motley Fool

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

August 03, 2026

GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

August 01, 2026

Guardant Health Q2 Earnings Call Highlights ↗

July 31, 2026

Via MarketBeat

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

July 30, 2026

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

July 30, 2026

Guardant Health to Participate in Upcoming Investor Conferences

July 29, 2026

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

July 28, 2026